Search Results – Inserm Transfert

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

BIO22282-T1

Drug Field of development:

Lymphoma Therapy Area:

Target Type of patent:

Garp as a biomarker and biotarget in t-cell malignancies

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has […]

BIO2114501-T1

Drug Field of development:

Lymphoma Therapy Area:

Target Type of patent:

Methods for the diagnosis and treatment of t cell-lymphomas

T-cell malignancies are a broad, heterogenous group of diseases and include T-cell lymphomas and T-cell leukemias. T-cell lymphomas are a […]

BIO22436-T1

Drug Field of development:

Lymphoma Therapy Area:

Method Type of patent:

Use of il-27 antagonists for the treatment of ebv-driven b

Epstein-Barr virus infection can engender severe B-cell lymphoproliferative disorders in immunocompromised individuals. In immunocompetent […]

BIO23255-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Target Type of patent:

Cd1a as a biomarker and biotarget in cutaneous t-cell lymphomas

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of CD1a by Sézary cells. CD1a therefore […]

BIO22403-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Target Type of patent:

Cd81 as a biomarker and biotarget in t-cell malignancies

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the overexpression of CD81 by Sézary cells. CD81 has also […]

BIO22282-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Target Type of patent:

Garp as a biomarker and biotarget in t-cell malignancies

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has […]

BIO22146-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Methods for the diagnosis and treatment of t cell-lymphomas

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]

BIO22037-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Target Type of patent:

Cd38 as a biomarker and biotarget in cell-lymphomas

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]

BIO21120-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Method Type of patent:

Methods for the diagnosis and treatment of t cell-lymphomas ccr8

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]

MECA19045-D1

Biomarker Field of development:

Lymphoma Therapy Area:

Method Type of patent:

New method using imaging analysis for assisting with prognosis of

The present invention relates to a method for assisting with lymphoma prognosis. The prognosis of therapeutic response of patients with lymphoma is […]

147

56

310

46

Our Technology Offers

Garp as a biomarker and biotarget in t-cell malignancies

Methods for the diagnosis and treatment of t cell-lymphomas

Use of il-27 antagonists for the treatment of ebv-driven b

Cd1a as a biomarker and biotarget in cutaneous t-cell lymphomas

Cd81 as a biomarker and biotarget in t-cell malignancies

Garp as a biomarker and biotarget in t-cell malignancies

Methods for the diagnosis and treatment of t cell-lymphomas

Cd38 as a biomarker and biotarget in cell-lymphomas

Methods for the diagnosis and treatment of t cell-lymphomas ccr8

New method using imaging analysis for assisting with prognosis of

You might also be interested in

Methods of treating familial adenomatous polyposis

Engraftment of engineered mesenchymal stromal

Composition comprising furin-inhibited car

Methods and pharmaceutical compositions for

Inhibitor of the heterochromatin protein 1 (hp1)

Methods and pharmaceutical compositions for

Method for treating cancer

Methods of treating cancer combining uros

Garp as a biomarker and biotarget in t-cell

Methods for the diagnosis and treatment of t

Methods and pharmaceutical composition for

Methods for the diagnosis and treatment of acute